同社の FBP18-PETスキャンによる評価も 同じannual Alzheimer's Association International Conferenceで報告されている
New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline
Study Results Presented at the Alzheimer's Association International Conference® 2015
https://investor.lilly.com/releasedetail.cfm?ReleaseID=923296
軽症アルツハイマー病患者への18ヶ月臨床治験、2012年失敗下に終了（アルツハイマー型認知症：ヒト抗アミロイドβモノクローナル抗体第3相治験：プライマリアウトカム到達しなかったが・・・ http://kaigyoi.blogspot.jp/2014/01/3.html）。しかし、1000名ほどさらに2年間投与し、病状進行緩徐化有意性しめされた。
Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease Results Presented at the Alzheimer's Association International Conference® 2015
https://investor.lilly.com/releasedetail.cfm?ReleaseID=923179
1 Liu-Seifert H, Siemers E, Holdrige K, Andersen S, et al. Delayed-Start of up to 3.5 Years in the Phase 3 Solanezumab Expedition Program in Mild Alzheimer's Disease. Presented at Alzheimer's Association International Conference (AAIC) 2015, July 18-23, 2015.
2 Doody, R., Thomas, R.G., Farlow, M., Iwatsubo, T., et al. (2014). Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. The New England Journal of Medicine, 370, 311-321. doi: 10.1056/NEJMoa1312889
3 Alzheimer's Association. 2015 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia 2015;11(3)332+.
4 Alzheimer's Disease International and World Health Organization Dementia Statistics. Available at: http://www.alz.co.uk/research/statistics. Accessed May 27, 2015.
Early signs drug delays Alzheimer's
– BBC News
– BBC News
solanezumabは、蛋白変性、アミロイドをターゲットにした薬剤で、アリセプトのような死にゆく神経細胞の機能改善だけを目的とする薬剤と根本的に違う・・・ということで期待は大
0 件のコメント:
コメントを投稿